Gene content    
CDKN2A ( by HUGO)
Cyclin-Dependent Kinase Inhibitor
Tumor suppressor gene
Cyclin-Dependent Kinase Inhibitor 2A
MLM
CDKN2
MTS1
Cyclin-Dependent Kinase Inhibitor 2A (Melanoma
P16
Inhibits CDK4)
Cyclin-Dependent Kinase 4 Inhibitor A
Multiple Tumor Suppressor 1
CDK4I
MTS-1
CMM2
P16
ARF
INK4
INK4A
P14
P14ARF
P16-INK4A
P16INK4
P16INK4A
P19
P19ARF
TP16
CDK4 Inhibitor P16-INK4
Cell Cycle Negative Regulator Beta
p14ARF
p16-INK4
p16-INK4a
p16INK4A
p19ARF
NCBI: 9p21    Ensembl: 9p21.3
CD2A1_HUMANSize: 132 amino acidsMass: 13903 Da

  • Subunit: Heterodimer with CDK4 or CDK6. Predominant p16 complexes contained CDK6. Interacts (isoforms 1,2 and 4) with CDK4 (both 'T-172'-phosphorylated and non-phosphorylated forms); the interaction inhibits cyclin D-CDK4 kinase activity. Interacts with ISCO2 Sequence caution: Sequence=AAB60645.1; Type=Erroneous initiation; 4 PDB 3D structures from [IMAGE] and Proteopedia [IMAGE] for CDKN2A: 1A5E (3D) [IMAGE] 1BI7 (3D) [IMAGE] 1DC2 (3D) [IMAGE] 2A5E (3D) [IMAGE]
  • Tissue specificity: Widely expressed but not detected in brain or skeletal muscle. Isoform 3 is pancreas-specific [IMAGE] Pathway & Disease-focused RT2 Profiler PCR Arrays including CDKN2A (see all 16): Lung Cancer in human mouse rat Autophagy in human mouse rat Prostate Can
  • Function:
    UniProtKB/Swiss-Prot Summary: CD2A1_HUMAN, P42771 Function: Acts as a negative regulator of the proliferation of normal cells by interacting strongly with CDK4 and CDK6. This inhibits their ability to interact with cyclins D and to phosphorylate the retinoblastoma protein UniProtKB/Swiss-Prot: CD2A2_HUMAN, Q8N726 Function: Capable of inducing cell cycle arrest in G1 and G2 phases. Acts as a tumor suppressor. Binds to MDM2 and blocks its nucleocytoplasmic shuttling by sequestering it in the nucleolus. This inhibits the oncogenic action of MDM2 by blocking MDM2-induced degradation of p53 and enhancing p53-dependent transactivation and apoptosis. Also induces G2 arrest and apoptosis in a p53-independent manner by preventing the activation of cyclin B1/CDC2 complexes. Binds to BCL6 and down-regulates BCL6-induced transcriptional repression. Binds to E2F1 and MYC and blocks their transcriptional activator activity but has no effect on MYC transcriptional repression. Binds to TOP1/TOPOI and stimulates its activity. This complex binds to rRNA gene promoters and may play a role in rRNA transcription and/or maturation. Interacts with NPM1/B23 and promotes its polyubiquitination and degradation, thus inhibiting rRNA processing. Interacts with COMMD1 and promotes its 'Lys63'-linked polyubiquitination. Interacts with UBE2I/UBC9 and enhances sumoylation of a number of its binding partners including MDM2 and E2F1. Binds to HUWE1 and represses its ubiquitin ligase activity. May play a role in controlling cell proliferation and apoptosis during mammary gland development. Isoform 6 may be involved in regulation of autophagy and caspase-independent cell death; the short-lived mitochondrial isoform is stabilized by C1QBP
  • Similarity:
    Belongs to the CDKN2 cyclin-dependent kinase inhibitor family
                          
    Contains 4 ANK repeats [IMAGE]
  • Protein Domain/Family    
    Source ID Domain Name Type
    InterProIPR002110Ankyrin_rptAnkyrinRepeat
    IPR010868Cyclin_kinase-Inhib_2ACyclin-dependent kinase inhibitor 2a p19Arf, N-terminalDomain

    Gene Ontology    
    Type Term Evidence Source Pub
    Biological Process activation of cysteine-type endopeptidase activity involved in apoptotic process IMP GOA 12082630
    apoptotic mitochondrial changes IMP GOA 12082630
    cell cycle arrest IMP GOA 16243918
    cell cycle arrest IDA GOA 15149599
    cellular senescence IMP GOA 16243918
    G1/S transition of mitotic cell cycle IDA GOA 10208428
    negative regulation of cell growth IDA GOA 10208428
    negative regulation of cell proliferation IMP GOA 16243918
    negative regulation of cell proliferation IDA GOA 15149599
    negative regulation of cell-matrix adhesion IMP GOA 10205165
    negative regulation of cyclin-dependent protein serine/threonine kinase activity IDA GOA 8259215
    negative regulation of NF-kappaB transcription factor activity IDA GOA 10353611
    negative regulation of phosphorylation IDA GOA 10208428
    negative regulation of protein kinase activity IMP GOA 15582998
    negative regulation of transcription, DNA-templated IMP GOA 16901784
    positive regulation of cell cycle arrest IDA GOA 9529249
    positive regulation of cellular senescence IMP GOA 16901784
    positive regulation of DNA damage response, signal transduction by p53 class mediator IDA GOA 9529249
    positive regulation of protein sumoylation IMP GOA 19057511
    positive regulation of transcription from RNA polymerase II promoter IDA GOA 17569660
    positive regulation of transcription, DNA-templated IDA GOA 17569660
    protein destabilization IDA GOA 9529249
    protein K63-linked ubiquitination IDA GOA 18305112
    protein polyubiquitination IDA GOA 18305112
    protein stabilization IDA GOA 10360174
    Ras protein signal transduction IEP GOA 9054499
    regulation of G2/M transition of mitotic cell cycle IMP GOA 15582998
    regulation of protein export from nucleus IMP GOA 10360174
    Cellular Component colocalizes_with nuclear body IDA GOA 10360174
    cytoplasm IDA GOA 16243918
    nucleoplasm IDA GOA 10360174
    nucleus IDA GOA 16243918
    protein complex IDA GOA 9529249
    Molecular Function cyclin-dependent protein serine/threonine kinase inhibitor activity IDA GOA 8259215
    NF-kappaB binding IDA GOA 10353611
    p53 binding IPI GOA 9529249
    protein binding IPI GOA 11278317
    protein kinase binding IPI GOA 8259215
    transcription factor binding IPI GOA 19057511

    Disorder & Mutation    
    Source Disease
    SWISS-PROTFamilial atypical multiple mole melanoma-pancreatic carcinoma syndrome (FAMMMPC) [MIM:606719]: An inherited cancer predisposition syndrome characterized by an increased risk of developing malignant melanoma and/or pancreatic cancer. Mutation carriers within families may develop either or both types of cancer. Note=The disease is caused by mutations affecting the gene represented in this entry
    SWISS-PROTMelanoma, cutaneous malignant 2 (CMM2) [MIM:155601]: A malignant neoplasm of melanocytes, arising de novo or from a pre-existing benign nevus, which occurs most often in the skin but also may involve other sites. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry
    SWISS-PROTNote=The association between cutaneous and uveal melanomas in some families suggests that mutations in CDKN2A may account for a proportion of uveal melanomas. However, CDKN2A mutations are rarely found in uveal melanoma patients
    SWISS-PROTLi-Fraumeni syndrome (LFS) [MIM:151623]: Autosomal dominant familial cancer syndrome that in its classic form is defined by the existence of a proband affected by a sarcoma before 45 years with a first degree relative affected by any tumor before 45 years and another first degree relative with any tumor before 45 years or a sarcoma at any age. Other clinical definitions for LFS have been proposed (PubMed:8118819 and PubMed:8718514) and called Li-Fraumeni like syndrome (LFL). In these families affected relatives develop a diverse set of malignancies at unusually early ages. Four types of cancers account for 80% of tumors occurring in TP53 germline mutation carriers: breast cancers, soft tissue and bone sarcomas, brain tumors (astrocytomas) and adrenocortical carcinomas. Less frequent tumors include choroid plexus carcinoma or papilloma before the age of 15, rhabdomyosarcoma before the age of 5, leukemia, Wilms tumor, malignant phyllodes tumor, colorectal and gastric cancers. Note=The disease is caused by mutations affecting the gene represented in this entry

    CDKN2A cross reference    
    PubMed OMIM Entrez Gene NCKU SNP Nucleotide UniProt Genome Data Viewer HomoloGene